Guillermo L Chantada

Summary

Publications

  1. doi request reprint SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries
    Guillermo Chantada
    Hospital de Pediatría SAMIC Prof Dr Juan P Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 60:719-27. 2013
  2. doi request reprint Results of a prospective study for the treatment of unilateral retinoblastoma
    Guillermo L Chantada
    Hemato Oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 55:60-6. 2010
  3. doi request reprint A phase I study of periocular topotecan in children with intraocular retinoblastoma
    Guillermo L Chantada
    Hematology Oncology, Hospital J P Garrahan, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 50:1492-6. 2009
  4. doi request reprint Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 52:218-22. 2009
  5. doi request reprint Familial retinoblastoma in developing countries
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 53:338-42. 2009
  6. ncbi request reprint Outcome of patients with retinoblastoma and postlaminar optic nerve invasion
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital J P Garrahan, Buenos Aires, Argentina
    Ophthalmology 114:2083-9. 2007
  7. ncbi request reprint Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina, and Department of Pathology, University of Sao Paulo, Brazil
    Pediatr Blood Cancer 49:256-60. 2007
  8. doi request reprint Strategies to manage retinoblastoma in developing countries
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 56:341-8. 2011
  9. doi request reprint Retinoblastoma: lessons and challenges from developing countries. Ellsworth Lecture 2011
    Guillermo L Chantada
    Hemato Oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina
    Ophthalmic Genet 32:196-203. 2011
  10. doi request reprint Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    J Pediatr Hematol Oncol 31:325-9. 2009

Collaborators

Detail Information

Publications29

  1. doi request reprint SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries
    Guillermo Chantada
    Hospital de Pediatría SAMIC Prof Dr Juan P Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 60:719-27. 2013
    ..Recommendations are provided for staging and treatment of unilateral and bilateral retinoblastoma and counseling of families for whom compliance is an issue...
  2. doi request reprint Results of a prospective study for the treatment of unilateral retinoblastoma
    Guillermo L Chantada
    Hemato Oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 55:60-6. 2010
    ..Few prospective studies about the management of unilateral retinoblastoma with pathology risk factors (PRFs) have been published...
  3. doi request reprint A phase I study of periocular topotecan in children with intraocular retinoblastoma
    Guillermo L Chantada
    Hematology Oncology, Hospital J P Garrahan, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 50:1492-6. 2009
    ..To identify the maximum tolerated dose and dose-limiting toxicity of periocular topotecan in patients with relapsed or resistant intraocular retinoblastoma who are facing imminent enucleation...
  4. doi request reprint Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 52:218-22. 2009
    ..There is little information on the outcome of patients with retinoblastoma and tumor at the resection margin of the optic nerve...
  5. doi request reprint Familial retinoblastoma in developing countries
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 53:338-42. 2009
    ..Although screening for familial retinoblastoma has been shown to be beneficial we suspected that such screening programs may be less than optimal in developing countries (DC)...
  6. ncbi request reprint Outcome of patients with retinoblastoma and postlaminar optic nerve invasion
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital J P Garrahan, Buenos Aires, Argentina
    Ophthalmology 114:2083-9. 2007
    ..To evaluate the outcome of patients with retinoblastoma and postlaminar optic nerve invasion (PLONI)...
  7. ncbi request reprint Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina, and Department of Pathology, University of Sao Paulo, Brazil
    Pediatr Blood Cancer 49:256-60. 2007
    ..To assess the outcome and determine risk factors for extraocular relapse in patients with retinoblastoma who had been enucleated after failure of chemoreduction...
  8. doi request reprint Strategies to manage retinoblastoma in developing countries
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 56:341-8. 2011
    ..Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence...
  9. doi request reprint Retinoblastoma: lessons and challenges from developing countries. Ellsworth Lecture 2011
    Guillermo L Chantada
    Hemato Oncology Department, Hospital JP Garrahan, Buenos Aires, Argentina
    Ophthalmic Genet 32:196-203. 2011
    ..There is an association between the socioeconomic indicators of a country's development with the chances of survival and treatment adherence. Strategies for obtaining a better outcome are depicted in this review...
  10. doi request reprint Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    J Pediatr Hematol Oncol 31:325-9. 2009
    ..To identify clinical features at presentation to help in detecting patients with retinoblastoma and pathology risk factors (PRFs) preoperatively, and therefore selecting a high-risk population that could benefit from preoperative treatment...
  11. ncbi request reprint Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country
    Guillermo L Chantada
    Department of Hematology Oncology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 44:455-60. 2005
    ..Chemoreduction is used for the treatment of retinoblastoma in industrialized nations; however, there are fewer data from developing countries. Before the implementation of this program, radiotherapy was used in almost all preserved eyes...
  12. ncbi request reprint Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma
    Paula Taich
    Unidad de Farmacocinética Clínica, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
    Ophthalmology 121:889-97. 2014
    ..To assess the antitumor activity, toxicity, and plasma pharmacokinetics of the combination of melphalan and topotecan for superselective ophthalmic artery infusion (SSOAI) treatment of children with retinoblastoma...
  13. doi request reprint Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA
    Viviana E Laurent
    Hematology Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina
    Eur J Cancer 49:2892-9. 2013
    ....
  14. ncbi request reprint World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group
    Guillermo L Chantada
    Hospital JP Garrahan, Buenos Aires, Argentina and International Outreach Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:692-4. 2008
    ..Internet meetings are a valuable mechanism for enabling participation from under-resourced countries in the development of cooperative studies...
  15. doi request reprint Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma
    Paula Schaiquevich
    CONICET Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 60:766-70. 2013
    ..This study compares the efficacy and toxicity of intra-arterial ophthalmic artery chemotherapy (IAO) to our historical cohort of sequential periocular and systemic chemotherapy in such patients...
  16. ncbi request reprint Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina
    Guillermo L Chantada
    Service of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 61:821-6. 2014
    ..Few studies were reported from developing countries regarding patient outcome and ocular survival in children with bilateral retinoblastoma treated with chemoreduction compared to external beam radiotherapy (EBRT)...
  17. doi request reprint Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients
    Guillermo L Chantada
    Service of Hematology Oncology, Hospital J P Garrahan, Buenos Aires, Argentina
    JAMA Ophthalmol 131:1127-34. 2013
    ..Different staging systems for extraocular retinoblastoma have been published, but to date they have not been validated in large cohorts...
  18. doi request reprint Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients
    Paula Schaiquevich
    CONICET, Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan, and Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 53:4205-12. 2012
    ..To characterize melphalan pharmacokinetics after superselective ophthalmic artery infusion (SSOAI) in animals and children with retinoblastoma...
  19. ncbi request reprint Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy
    Angel M Carcaboso
    Departments of Pharmacology, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 48:3761-7. 2007
    ..To determine the extent and the mechanism by which topotecan, a candidate agent for the treatment of retinoblastoma, gains access to the vitreous when administered by periocular injection or intravenous infusion...
  20. doi request reprint Episcleral implants for topotecan delivery to the posterior segment of the eye
    Angel M Carcaboso
    Department of Pharmacology, University of Buenos Aires, Buenos Aires, Argentina
    Invest Ophthalmol Vis Sci 51:2126-34. 2010
    ....
  21. doi request reprint Outcome of children with retinoblastoma and isolated choroidal invasion
    Andrea Bosaleh
    Department of Pathology, Hospital JP Garrahan, Buenos Aires, Argentina
    Arch Ophthalmol 130:724-9. 2012
    ....
  22. ncbi request reprint An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    J Pediatr Hematol Oncol 28:369-73. 2006
    ..GD2 was intensively expressed and it may also be used to monitor disease response and the presence of minimal residual disease...
  23. ncbi request reprint Strategies to manage retinoblastoma in developing countries
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 56:341-8. 2011
    ..Pediatr Blood Cancer 2011;56:341-348. © 2010 Wiley-Liss, Inc...
  24. ncbi request reprint Activity of topotecan in retinoblastoma
    Guillermo L Chantada
    Department of Hematooncology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
    Ophthalmic Genet 25:37-43. 2004
    ..To report our experience with topotecan in children with relapsed/refractory metastatic and intraocular retinoblastoma...
  25. doi request reprint Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model
    Paula Schaiquevich
    Clinical Pharmacokinetics Unit, CONICET Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
    Retina 32:387-95. 2012
    ..To characterize the vitreous and plasma pharmacokinetics of topotecan after ophthalmic artery infusion (OAI) subsequent to superselective artery catheterization and to compare it with periocular injection (POI)...
  26. doi request reprint Clinical presentation of retinoblastoma in a middle-income country
    Elliot Navo
    Department of Medicine, New York Hospital of Queens, NY, USA
    J Pediatr Hematol Oncol 34:e97-101. 2012
    ..001). Retinoblastoma is diagnosed in later stages in our setting and presentation with eye enlargement and increasing age at diagnosis correlate with worse outcome...
  27. ncbi request reprint Colorectal carcinoma in children, adolescents, and young adults
    Guillermo L Chantada
    Hospital J P Garrahan, Buenos Aires, Argentina
    J Pediatr Hematol Oncol 27:39-41. 2005
    ..Thirteen patients died of progressive disease, 1 died of a non-tumor-related cause, and 1 is still on treatment. Patients younger than 20 years have a poorer prognosis, probably because of advanced disease on presentation...
  28. doi request reprint Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma
    Viviana E Laurent
    Laboratory of Molecular Oncology, Quilmes National University, Buenos Aires, Argentina
    Mol Med Report 3:253-9. 2010
    ..Hence, GD2 synthase mRNA detection through an optimized nested RT-PCR assay is a promising tool for the assessment of minimal disseminated disease in enucleated patients...
  29. ncbi request reprint Lack of activity of oral etoposide for relapsed intraocular retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ophthalmic Genet 25:25-9. 2004
    ..Because oral etoposide has been found to be highly effective in patients with relapsed medulloblastoma and neuroblastoma who had previously received intravenous etoposide, we investigated its use for intraocular retinoblastoma...